
First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

CatalYm GmbH raises €50m to push visugromab development
Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...

A ray of hope in leukaemia
In 2021, Alyssa, a 13-year-old girl from Leicester, after a long struggle with what her family thought to be colds, viruses, and general tiredness,...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

SOTIO licences first cancer ADC from LegoChem Biosciences
The announcement of Czech immuno-oncology specialist SOTIO AS reported came along with promising safety and efficacy Phase I results of LegoChem...

Jolt Capital boosts BC Platforms with $20m
Espoo-based BC Platforms, an international healthcare data provider and software developer, in November has baged an investment of $20m from the...